DARVON-N W/ ASA
LOE Approachingaspirin; propoxyphene napsylate
NDAORALCAPSULE
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N W/ ASA is an oral capsule combination product containing propoxyphene napsylate and aspirin, approved in 1971. It is an opioid analgesic combined with an NSAID, indicated for mild-to-moderate pain relief. The propoxyphene component acts as a weak opioid agonist while aspirin provides anti-inflammatory and analgesic benefits.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked job opportunities, this represents a declining commercial franchise with minimal team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only 1 linked job opportunity exists for DARVON-N W/ ASA, reflecting the product's minimal commercial footprint and approaching obsolescence. This is a poor career destination for professionals seeking growth, visibility, or long-term stability in pharmaceutical careers.
DOCTORA
1 open roles linked to this drug
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.